[ Consultations are increasing! ] The first step to accelerate MASH research
As you may already know, the United States Food and Drug Administration (FDA) announced the approval of Rezdiffra (resmetirom), developed by Madrigal Pharmaceuticals, as the first treatment for MASH.
FDA approved first MASH treatment
If you are developing a MASH treatment drug under these circumstances, by first contacting a specialized CRO, you will be able to rapidly advance your research and development to the next step.
In fact, right after the approval was announced, we received a lot of inquiries, and many researchers are now taking the next step.
When considering a project internally, it is necessary to first collect and organize information related to MASH development, and it takes a lot of time to research those, but a specialized CRO with strengths in MASH can do this. We have organized the following frequently requested information.
– Results of non-clinical and clinical studies of Rezdiffra (resmetirom)
– MASH clinical trial status
– Model mice and analysis items selected for non-clinical studies
– Regarding the future flow of MASH therapeutic drug development
In the case of clients who contacted us immediately after the approval of a MASH treatment, they have already decided to conduct a study and are quickly moving towards the next step.
In the case of the above clients, the following steps have been taken to conduct the study.
1. Hearing about the development status and sharing MASH development information
2. Study planning according to the content of the interview
3. Proposals for model mice and test designs
Many of SMC Laboratories’ strengths lay in the MASH field, and we are able to quickly move forward with in-house decision-making by understanding the current MASH development status and providing proposals tailored to the development strategy and compounds.
As pioneers in the field of MASH, we have conducted more than 800 efficacy studies using the STAMTM-HCC/IO+ model, evaluated many candidate drugs for the treatment of MASH, of which more than 15 compounds are in clinical trials.
And because we are a CRO with strengths in the MASH field, we are able to not only give you suggestions using the STAMTM-HCC/IO+ model, but also provide appropriate information as well as proposals tailored to your issues and difficulties.
Since we possess extensive know-how in MASH research, so we have the ability to give you the best advices.
As the industry as a whole looks forward to the next approval, we are confident that we can greatly help your success.